Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups (This dataset does not contain this module)
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE163836

Dataset summary for GSE163836

Datast information	Dataset	GSE163836
	PMID	36409824
	Raw data ID/link	PRJNA685991
	Organism	Homo sapiens
	Source	FCIBC02 cell line
	Tissue	Cell line
	Cancer type level1	Breast cancer
	Cancer type level2	Inflammatory breast cancer
	Regimen	paclitaxel
	Drug type	Chemotherapy
	Sample size	resistant 1, sensitive 1
	Cell number	7358
	Extract protocol	10x genomics
	Data processing	CellRanger
	Public date	Public on Nov 02, 2022
	Description	This dataset has 1 cell line with a sensitive pre-treatment sample and a resistant post-treatment sample.

Top

Drug summary for GSE163836

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"Paclitaxel"	DB01229	small molecule	TUBB1; BCL2; MAP4; MAP2; MAPT; NR1I2	Q9H4B7; P10415; P27816; P11137; P10636; O75469

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types	Umap of conditions
Umap of cell clusters	Cell ratio of drug-resistant and sensitive groups within each cluster

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
KIF22	ENSG00000079616	0.361743	0.00e+00	4.22e-43	0.668	0.551	Malignant cells	NA
BRI3	ENSG00000164713	0.358387	0.00e+00	0.00e+00	0.954	0.901	Malignant cells	NA
EPRS	NA	0.357439	0.00e+00	0.00e+00	0.831	0.776	Malignant cells	NA
ARHGAP21	ENSG00000107863	0.357403	0.00e+00	0.00e+00	0.37	0.168	Malignant cells	NA
UBA52	ENSG00000221983	0.356026	0.00e+00	0.00e+00	1	1	Malignant cells	NA
SNRPD3	ENSG00000100028	0.355137	0.00e+00	0.00e+00	0.895	0.829	Malignant cells	NA
CALU	ENSG00000128595	0.354489	0.00e+00	0.00e+00	0.749	0.652	Malignant cells	NA
C4orf48	ENSG00000243449	0.353218	0.00e+00	0.00e+00	0.969	0.912	Malignant cells	NA
ZFP36L1	ENSG00000185650	0.350022	0.00e+00	0.00e+00	0.896	0.805	Malignant cells	NA
ATP5E	NA	0.349979	0.00e+00	0.00e+00	1	0.999	Malignant cells	NA
ENAH	ENSG00000154380	0.349956	0.00e+00	1.84e-42	0.69	0.595	Malignant cells	NA
SERF2	ENSG00000140264	0.349371	0.00e+00	0.00e+00	1	1	Malignant cells	NA
TOP2A	ENSG00000131747	0.347742	2.17e-08	3.70e-04	0.406	0.369	Malignant cells	NA
TPM1	ENSG00000140416	0.347468	2.31e-42	3.96e-38	0.981	0.936	Malignant cells	NA
KLF2	ENSG00000127528	0.344778	8.33e-20	1.43e-15	0.472	0.389	Malignant cells	NA
HSPA2	ENSG00000126803	0.344364	8.32e-43	1.42e-38	0.738	0.646	Malignant cells	NA
SUMO2	ENSG00000188612	0.34235	0.00e+00	0.00e+00	0.993	0.987	Malignant cells	NA
JAG1	ENSG00000101384	0.341254	0.00e+00	0.00e+00	0.393	0.22	Malignant cells	NA
GNAQ	ENSG00000156052	0.341194	2.20e-39	3.76e-35	0.543	0.418	Malignant cells	NA
ACTR6	ENSG00000075089	0.3401	0.00e+00	1.40e-44	0.438	0.271	Malignant cells	NA
ESRP1	ENSG00000104413	0.337674	8.51e-43	1.46e-38	0.537	0.4	Malignant cells	NA
COX6C	ENSG00000164919	0.337364	0.00e+00	0.00e+00	1	1	Malignant cells	NA
RSL24D1	ENSG00000137876	0.334886	0.00e+00	0.00e+00	0.867	0.799	Malignant cells	NA
LAMTOR4	ENSG00000188186	0.334859	0.00e+00	0.00e+00	0.936	0.894	Malignant cells	NA
HSPB1	ENSG00000106211	0.33463	0.00e+00	0.00e+00	1	0.982	Malignant cells	NA
TUBB4B	ENSG00000188229	0.334385	9.81e-45	1.67e-40	0.851	0.781	Malignant cells	NA
TKT	ENSG00000163931	0.334074	0.00e+00	0.00e+00	0.983	0.961	Malignant cells	NA
CNFN	ENSG00000105427	0.333638	2.66e-44	4.66e-40	0.535	0.388	Malignant cells	NA
TPM3	ENSG00000143549	0.332511	0.00e+00	0.00e+00	0.986	0.973	Malignant cells	NA
TOB1	ENSG00000141232	0.331218	0.00e+00	0.00e+00	0.369	0.192	Malignant cells	NA
PUM1	ENSG00000134644	0.329962	1.40e-45	1.22e-41	0.459	0.302	Malignant cells	NA
HSP90AA1	ENSG00000080824	0.328249	0.00e+00	0.00e+00	0.999	1	Malignant cells	NA
PLEC	ENSG00000178209	0.326659	1.72e-42	2.95e-38	0.459	0.309	Malignant cells	NA
H2AFJ	NA	0.325619	0.00e+00	0.00e+00	0.981	0.945	Malignant cells	NA
SFPQ	ENSG00000116560	0.324637	6.70e-42	1.15e-37	0.783	0.727	Malignant cells	NA
RPL39	ENSG00000198918	0.321126	0.00e+00	0.00e+00	1	1	Malignant cells	NA
DDX21	ENSG00000165732	0.318844	5.44e-43	9.30e-39	0.787	0.722	Malignant cells	NA
METAP2	ENSG00000111142	0.31636	9.76e-39	1.67e-34	0.639	0.539	Malignant cells	NA
PTPRF	ENSG00000142949	0.316319	0.00e+00	0.00e+00	0.846	0.784	Malignant cells	NA
HNRNPAB	ENSG00000197451	0.31604	0.00e+00	2.47e-43	0.955	0.914	Malignant cells	NA
NDUFS6	ENSG00000145494	0.314781	0.00e+00	0.00e+00	0.996	0.981	Malignant cells	NA
EGFR	ENSG00000146648	0.313595	0.00e+00	0.00e+00	0.338	0.16	Malignant cells	NA
SMIM22	ENSG00000267795	0.312687	0.00e+00	4.76e-44	0.496	0.319	Malignant cells	NA
ACTN4	ENSG00000282844	0.312142	4.92e-41	8.41e-37	0.773	0.715	Malignant cells	NA
RGS10	ENSG00000148908	0.309865	0.00e+00	0.00e+00	0.941	0.904	Malignant cells	NA
SLCO3A1	ENSG00000176463	0.309712	0.00e+00	1.40e-45	0.328	0.162	Malignant cells	NA
CCL28	ENSG00000151882	0.309152	2.92e-40	4.99e-36	0.422	0.261	Malignant cells	NA
PRRC2C	ENSG00000117523	0.307166	0.00e+00	0.00e+00	0.972	0.961	Malignant cells	NA
GUCY1A3	NA	0.305963	1.40e-45	1.32e-41	0.899	0.828	Malignant cells	NA
SLC26A2	ENSG00000155850	0.305618	8.65e-32	1.48e-27	0.379	0.244	Malignant cells	NA

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	9.20e-12	4.60e-11	1761	781	113	23467	Malignant cells	ANXA2,AURKA,BAX,CDK4,CDK6,CERS2,CRYAB,DCTD,DNMT1,EGFR,FADD,GSTP1,HMGA1,HSPA1A,ID1,IDH2,IFI27,JUN,PKM,MTA1,NFE2L2,PARP1,PEA15,RPS6,S100A4,ST3GAL4,SOX4,SOX9,STMN1,TPD52,YWHAZ,SLC25A5,ALDH1A3,ANXA1,ATG3,BAD,BID,BRD4,BTG1,CCND1,CCNE1,CCNG1,CD44,CDKN2A,CLTC,CAPNS1,DUSP1,DUSP2,DHFR,E2F1,EHF,EIF3A,HSP90B1,EZH2,GAPDH,G6PD,HAX1,HDAC3,HMGB2,HSPB1,EIF4A1,EIF4A3,ITGB1,JAG1,KEAP1,LDHA,MGMT,MOB1A,MAP2K1,MSH6,MYBL2,NOTCH2,NOTCH3,NTRK2,NUCKS1,OAZ2,PABPC1,PGK1,AGPAT2,POMP,PRKDC,PSMB5,RAC1,RAF1,RAB22A,RRM2,RND3,HNRNPA1,RSU1,SDC2,SDHB,SFPQ,SIAH2,SMC4,SMUG1,TPT1,UCP2,YBX1,YEATS4,ZNF217,ENO1,FASN,GNAS,CALR,GNAQ,CEBPD,EIF4EBP1,TM7SF2,PMVK,EBP,NUPR1,SIRT6,ACAT2
Aberration of the Drug's Therapeutic Target	1.70e-02	4.20e-02	1761	90	13	23467	Malignant cells	CDK4,CDK6,EGFR,IDH2,CDKN2A,DHFR,EZH2,MAP2K1,MSH6,SF3B1,COMT,AKR1B1,TOP2A
Drug Inactivation by Structure Modification	1.40e-01	2.30e-01	1761	27	4	23467	Malignant cells	GSTP1,CYP1B1,NME1,CMPK1
Irregularity in Drug Uptake and Drug Efflux	7.80e-01	9.70e-01	1761	37	2	23467	Malignant cells	ABCB1,SLC34A2
Epigenetic Alteration of DNA, RNA or Protein	1.00e+00	1.00e+00	1761	455	13	23467	Malignant cells	DNMT1,EGFR,H2AFY,IDH2,MTA1,CDKN2A,EZH2,GAPDH,SMC4,TIMP1,MALAT1,SMYD2,MT-CO2

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	transfac_pro__M07436	3.7	0.0656	WT1 (directAnnotation).	Malignant cells
	transfac_pro__M07461	3.69	0.0655	KLF1; KLF10; KLF11; KLF12; KLF13; KLF15; KLF16; KLF17; KLF2; KLF3; KLF4; KLF5; KLF6; KLF7; KLF8; KLF9 (directAnnotation).	Malignant cells
	transfac_pro__M04916	3.66	0.0652	TAF1 (directAnnotation).	Malignant cells
	metacluster_3.14	3.62	0.0648	WT1; WT1 (directAnnotation).	Malignant cells
	transfac_pro__M01219	3.6	0.0647	SP1 (directAnnotation). SP3 (inferredBy_Orthology).	Malignant cells
	hdpi__TFAM	3.56	0.0643	TFAM (directAnnotation).	Malignant cells
	transfac_pro__M02089	3.53	0.064	E2F3 (directAnnotation).	Malignant cells
	transfac_pro__M07329	3.53	0.064	SP7 (directAnnotation).	Malignant cells
	transfac_pro__M01122	3.5	0.0638	ZNF219 (directAnnotation).	Malignant cells
	kznf__ZNF311_Imbeault2017_RP_ChIP-seq	3.49	0.0636	ZNF311 (directAnnotation).	Malignant cells

Page: 1 2 3 4 5

Motifs and TFs regulating down-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	8.13	0.0658	ETS2 (directAnnotation).	Malignant cells
	metacluster_34.4	7.46	0.0621	ETS1; ETS1; ETS1; HCFC1; SIX5; SIX5; SIX5; SIX5; SMARCC2; SMARCC2; THAP11; THAP11; ZNF143; ZNF143; ZNF143; ZNF143 (directAnnotation). TBX2; THAP11; THAP11; ZNF143 (inferredBy_Orthology).	Malignant cells
	metacluster_191.3	6.8	0.0584	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).	Malignant cells
	jaspar__MA1483.2	6.71	0.0579	ELF2 (directAnnotation).	Malignant cells
	metacluster_191.2	6.66	0.0577	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_166.4	6.49	0.0567	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	6.15	0.0549	ELF1; MEIS1 (directAnnotation).	Malignant cells
	transfac_pro__M04826	6.13	0.0547	EP300 (directAnnotation).	Malignant cells
	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	6.11	0.0546	ETV5; HOXA2 (directAnnotation).	Malignant cells
	hdpi__FLI1	5.85	0.0532	FLI1 (directAnnotation).	Malignant cells

Page: 1 2 3 4 5 6

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
ELF3	metacluster_166.4	up	Malignant cells	NA
ELF5	metacluster_166.4	up	Malignant cells	NA
FOS	metacluster_174.2	up	Malignant cells	NA
PBX1	metacluster_174.2	up	Malignant cells	NA
ZNF580	metacluster_138.2	up	Malignant cells	NA
KLF2	transfac_pro__M07461	up	Malignant cells	NA
MAZ	homer__GGGGGGGG_Maz	up	Malignant cells	NA
KLF2	transfac_pro__M08819	up	Malignant cells	NA
MAZ	metacluster_133.2	up	Malignant cells	NA
EHF	metacluster_191.3	down	Malignant cells	NA

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."